Finance

Beta
Lists
ZBIO:NASDAQ
Zenas Biopharma Inc
$25.87
+4.86%
(+1.20) 1D
$26.39
+2.01% (+0.52)
After hours
Closed: Jun 26, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
$24.26
High
$26.00
Low
$23.90
Mkt. cap
1.63B
Avg. vol.
672.86K
Volume
3.50M
52-wk high
$44.60
52-wk low
$8.91
EPS
-$8.45
Shares outstanding
63.13M
No. of employees
167
Open
$24.26
High
$26.00
Low
$23.90
Mkt. cap
1.63B
Avg. vol.
672.86K
Volume
3.50M
52-wk high
$44.60
52-wk low
$8.91
EPS
-$8.45
Shares outstanding
63.13M
No. of employees
167
News stories
From sources across the web
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitezenasbio.com
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current $25.87
$55.00 (+112.60%)
Average
$41.40 (+60.03%)
Lowest
$22.00 (-14.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$44.00
+70.1%
06/25/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$44.00
+70.1%
06/08/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$55.00
+112.6%
06/05/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
$22.00
-15%
05/14/2026
David Nierengarten
Wedbush
Buy
Maintained
$45.00
+73.9%
05/14/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$41.00
+58.5%
05/13/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$55.00
+112.6%
03/17/2026
Martin Fan
Wedbush
Buy
Maintained
$45.00
+73.9%
03/17/2026
Last report
May 13, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.46 / -$1.54
+5.19%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
43.03M
34.40M
55.72M
60.44M
Cost of revenue
43.03M
34.40M
55.72M
60.44M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.14M
13.18M
15.59M
16.91M
Operating expense
12.14M
13.18M
15.59M
16.91M
Total operating expenses
55.16M
47.58M
71.31M
77.35M
Operating income
-55.16M
-47.58M
-71.31M
-77.35M
Other non operating income
2.96M
1.08M
-7.48M
-24.00K
EBT including unusual items
-52.20M
-51.50M
-240.34M
-80.99M
EBT excluding unusual items
-52.20M
-46.50M
-73.66M
-80.99M
Income tax expense
20.00K
-
106.00K
-
Effective tax rate
-0.04%
-
-0.04%
-
Other operating expenses
-
-
-
-
Net income
-52.22M
-51.50M
-240.44M
-80.99M
Net profit margin
-
-
-
-
Earnings per share
-1.25
-1.22
-1.39
-1.46
Interest and investment income
-
-
12.15M
3.02M
Interest expense
-
-
-7.33M
-6.63M
Net interest expenses
-
-
4.82M
-3.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
-55.15M
-47.57M
-71.30M
-77.34M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ZBIO
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer